Tag:
colorectal cancer
Latest Headlines
Latest Headlines
Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback
Sanofi and Regeneron's opened their update on the cancer drug Zaltrap (aflibercept) on a sweet note: The FDA has granted a priority review of their NDA for colorectal cancer.
Bayer bolsters blockbuster case for regorafenib with new PhIII data
Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.
RNA could predict cancer recurrence risk
Around a quarter of people with rectal cancer will experience a recurrence of their disease, and knowing the risk could help their monitoring and treatment.
Everist launches companion Dx, prognostics portfolio for colorectal cancer
Colorectal cancer is a growing disease burden in the U.S., with roughly 140,000 new cases being diagnosed each year, according to the National Cancer Institute . Ann Arbor, MI-based Everist Genomics, which we profiled in our 5 innovative Michigan companies report last year, is looking to combat the disease and allow doctors to find it early enough to help patients.
Urine test could point out colon cancers
Colon cancer diagnosis could one day be as easy as peeing in a pot. Well, perhaps that's simplifying things a little, but researchers at the Vanderbilt-Ingram Cancer Center have found a urine...
Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout
Boston Biomedical's focus on targeting cancer stem cells has paid off.
New Enzo test aims to boost colonoscopy compliance
Colon cancer is very common in the U.S. The American Cancer Society estimates that there were roughly 140,000 cases of colorectal cancers in the U.S. last year. Despite these numbers, many Americans...
New biomarker panel could support colorectal cancer diagnosis
Colorectal cancer is the second most common cause of cancer death in the West, linked largely to a love of booze, red meat and high-fat food combined with a lack of exercise. Further, symptoms are of
Curis shares plunge after lead drug flunks cancer trial
Cambridge, MA-based Curis ( CRIS ) has been handed a significant setback on its lead cancer program. The developer announced this morning that GDC-0449 flunked the primary endpoint in a Phase II
Poniard unveils positive picoplatin safety profile
Mid-stage studies of Poniard Pharmaceuticals' picoplatin delivered positive data for advanced colorectal cancer as well as advanced prostate cancer, setting the schedule for likely Phase III studies
